Dr Kashif Naseem Layout

specializing in addiction recovery

CALL TODAY

3642 Wheeler Rd Augusta, GA 30909

(706) 495-5896

KASHIF408@YAHOO.COM

Dr. Kashif Naseem

Contact Info 3642 Wheeler Rd Augusta, GA 30909

(706) 495-5896

Education •Conemaugh Valley Memorial Hospital Residency , Internal Medicine •King Edward Medical University Medical School Specialties Internal Medicine Certifications & Licensure •American Board of Internal Medicine Certified in Internal Medicine •GA State Medical License Active through 2018 •SC State Medical License Active through 2019 About

Dr. Kashif Naseem is an internist in Augusta, Georgia and is affiliated with Doctors Hospital. He received his medical degree from King Edward Medical University and has been in practice for more than 20 years. Dr. Naseem accepts several types of health insurance, listed below. He is one of 25 doctors at Doctors Hospital who specialize in Internal Medicine.

3642 WHEELER ROAD • AUGUSTA, GA 30909 706.495.5896 CONTACT US TODAY

WE ARE PROUD TO PROVIDE A HIGH LEVEL OF QUALITY CARE TO ALL OUR PATIENTS.

Are you missing 18%* of your Patients’ Positive Opioid Test Results? You may be without High Sensitivity Definitive Testing.

RESTORE BALANCE

LIFE AND

706.495.5896 CONTACT US 3642 Wheeler Road Augusta, GA 30909

Feeling Trapped?

Don’t face opioid addiction alone. Get help today.

3642 Wheeler Road Augusta, GA 30909 706-495-5896

SAMHSA PUBLISHES BEST PRACTICES ON MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER

Treatment Improvement Protocol 63, “Medications for Opioid Use Disorder,”

reviews the use of methadone, naltrexone, and

buprenorphine, the three FDA-approved medications to treat opioid use disorders.

Data indicate that OUD-treating medications are both cost effective and cost beneficial

The Substance Abuse and Mental Health Services Administration has published new guidance to help health care professionals better understand medications that can be used to treat Americans with opioid use disorder (OUD). Treatment Improvement Protocol (TIP) 63, “Medications for Opioid Use Disorder,” reviews the use of methadone, naltrexone, and buprenorphine, the three FDA-approved medications to treat opioid use disorders. TIP 63 provides guidance for health care professionals and addiction treatment providers on how to appropriately prescribe these medications and effectively support patients using these medications for OUD treatment. “We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Dr. Elinore F. McCance-Katz, assistant secretary for Mental Health and Substance Use. “TIP 63 emphasizes that increasing access to medications to treat opioid use disorder will help more people recover, enabling them to improve their health, living full and productive lives.” TIP 63 is part of SAMHSA’s larger response to the opioid crisis. More access to treatment with OUD medications is critical to closing the gap between treatment need and treatment availability and an important public health strategy. Data indicate that OUD-treating medications are both cost effective and cost beneficial.

DR KASHIF NASEEM 3642 Wheel Road Augusta, GA 30909 706-495-5896

Sign of the times Experts say the newly approved implant also provides a big boost to the concept of medication-assisted treatment (MAT) in general. For years, the idea that someone could achieve recovery through the use of drugs like methadone and buprenorphine was rejected by many professionals in the eld who saw complete abstinence as the only true sobriety. Many still hold that belief, but attitudes appear to be changing. Top government oŽcials say they want to increase the amount of MAT taking place at the country’s treatment centers. Several states as well as the federal government have enacted laws making it easier for physicians to prescribe medications like buprenorphine, but they say too few patients receive the medication they need. National Institute on Drug Abuse, in a statement. “is product will expand the treatment alternatives available to people suering from an opioid use disorder.” ] [ "Opioid abuse and addiction have taken a devastating toll on American families.” - Dr. Robert M. Cali, FDA Commissioner “Scientic evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more eective in the treatment of opioid use disorder than short-term detoxication programs aimed at abstinence,” said Dr. Nora Volkow, director of the

M

edication-assisted treatment is growing in popularity and acceptance among addiction recovery professionals. And now it’s taken a revolutionary step forward that could oer renewed hope to thousands of people struggling with an addiction to opioids. is summer, the U.S. Food and Drug Administration approved a new buprenorphine implant to treat opioid dependence. Buprenorphine had previously been available only as a pill or a dissolvable lm placed under the tongue. But the new implant, known as Probuphine, can administer a six-month dose of the drug to keep those dependent on opioids from using by reducing cravings and withdrawal symptoms. "Opioid abuse and addiction have taken a devastating toll on American families,” FDA Commissioner Dr. Robert M. Cali said in a statement. “We must do everything we can to make new, innovative treatment options available that can help patients regain control over their lives.” e implant comes in the form of four one-inch rods that are placed under the skin on the upper arm.e implant must be administered surgically and comes with the possibility of certain side eects, but experts say it could be more convenient and more eective for patients.ey say by eliminating the need to take pills, ll prescriptions and generally manage their medication, it makes it easier for people to focus on the other areas of their recovery while making it less likely someone will lapse in their treatment plan.

36

Brought toyou by:

Although the implant is certainly a new alternative, it has yet to show any increased success in keeping people from relapsing compared to the pill or lm tablet. In a study of the implant’s eectiveness, they found that 63 percent of people given the implant were free of illicit drugs at six months, compared to 64 percent of people who took buprenorphine by pill. Still, those rates are much higher than the success rates of people who follow abstinence-only treatment plans. And oŽcials hope the new implant will lead more people to get MAT, increasing the number of successful recoveries across the country.

37

THEY ARE MORE THAN YOU THINK LIKE YOU

80 percent of the babies born to heroin-addicted mothers are born addicts. Like mommy, like baby. (706)495-5896

3642 WHEELER ROAD • AUGUSTA, GA 30909 | 706.495.5896

not just a bad habit It’s NOT JUSTA BAD HABIT

Recent research and dialogue in the political sphere have brought long-simmering questions about addiction to the forefront: Is addiction truly a disease? Do addicts deserve to be treated like people who have a Recent res arch and ialogue in the political spher have brought long-sim ering questions about ad iction to the fore: Is addiction truly a disease? Do addicts deserve to b tr ated like people who hav a dise s that’s outside their control? disease that’s outside their control? While most researchers agree with the so-called disease model of addiction, stereotypes and cultural bias continue to stigmatize those with addiction because they made an initial choice to consume substances. However, Columbia University researchers point out that “choice does not determine whether 34 While most res archers agre with the so-called isease model of ad iction, ster otypes and cultural bias continue to stigmatize those with ad iction because they made an initial choice to consume substances. However, Columbia University res archers point out that “choice does not det rmine whether

something is a disease. Heart disease, diabetes and some forms of cancer involve personal choices like diet, exercise, sun exposure, etc. A disease is what happens in the body as a result of those choices.” Experts say that applying the distinction of choice to addiction creates biases that justify inadequate treatment. It begs the question New Jersey Gov. Chris Christie asked during a 2015 town hall meeting in New Hampshire. When Christie’s mother was diagnosed something is a disease. Heart disease, diabet s and some forms of cancer involve personal choices like diet, exercise, sun exposure, etc. A disease is what hap ens in the body as a result of those choices.” Experts ay that ap lying the distinction of choice to ad iction creates biases that justify inadequate treatment. It begs the question New Jersey Gov. Chris Christie asked uring a 2015 town hall me ting in New Hampshire. When Christie’s mother was diagnosed with lung cancer at 71 as a result of addiction to tobacco, he noted that with lung cancer at 71 as a result of ad iction to tobacco, he noted that

no one suggested that she should not be treated because she was “getting what she deserved,” he said. “Yet somehow, if it’s heroin or cocaine or alcohol, we say, ‘Ahh, they decided that, they’re getting what they deserve,’” Christie remarked. HOW ADDICTION WORKS After satisfying basic human needs like food, water, sleep and safety, people feel pleasure. That pleasure is brought by chemical releases in the brain. This is according to Columbia researchers, who note that the disease of addiction causes the brain to release high levels of those pleasure chemicals. Over time, brain functions of reward, motivation and memory are altered. After these brain systems are compromised, those with addiction can experience intense cravings for substance use, even in the face of harmful consequences. These changes can stay in the brain long after substance use desists. The changes may leave those struggling with addiction to be vulnerable to “physical and environmental cues they associate with substance use, also known as triggers, which can increase their risk of relapse,” write Columbia researchers.

not just a bad habit treatment and continued monitoring and support or recovery.

THE COLUMBIA RESEARCHERS DO HAVE SOME GOOD NEWS: Even the most severe, chronic form of the disorder can be manageable and reversible, usually with long term

35

While in REBUILDING

YOUR RELATIONSHIP

from Recovery

Addiction

3642 Wheeler Road • Augusta, GA 30909 | PH: (706)495-5896

I N AN EFFORT to encourage new treatments for opioid addiction, the Food and Drug Administration plans to begin permitting pharmaceutical companies to sell medications that help temper cravings, even if they don’t fully stop addiction. The change is part of a wider effort to expand access to so-called medication-assisted treatment, or MAT. The agency will issue draft guidelines in the next few weeks. A senior agency official provided details of the proposal to The New York Times. the agency said it would soon publish two guidances, recommendations for drugmakers, on the issue.

The new approach was signaled Saturday by the health and human services secretary, Alex M. Azar II, in remarks to the National Governors Association. Mr. Azar said the agency intended “to correct a misconception that patients must achieve total abstinence in order for MAT to be considered effective.” While the Trump administration has generally supported medication-assisted treatment, Mr. Azar’s predecessor, Tom Price, was not completely on board with it. Mr. Price caused an uproar among treatment experts when he dismissed some medications that reduce cravings through synthetic opioids last spring as substituting one opioid for another. He subsequently walked back those comments, saying officials should be open to a broad range of treatment options. Mr. Azar, who took office late last month, said he would work to reduce the stigma associated with addiction and addiction therapy, and would not treat it as a moral failing. The opioid epidemic is considered the most unrelenting drug crisis in United States history. In 2016, roughly 64,000 people were killed by drug overdoses, including from prescription opioid painkillers and heroin. to correct a misconception that patients must achieve total abstinence in order for MAT to be considered effective. Noting federal data showing that only one-third of specialty substance abuse treatment programs offer medication-assisted treatment, Mr. Azar said, “We want to raise that number — in fact, it will be nigh impossible to turn the tide on this epidemic without doing so.” Mr. Azar’s comments echo those of the F.D.A. chief, Dr. Scott Gottlieb, who has made battling opioid abuse a priority for his agency. Dr. Gottlieb has moved to reduce opioid prescriptions by doctors and dentists and to promote more medication- assisted treatment, defined as drugs used to stabilize brain chemistry, reduce or block the euphoric effects of opioids, relieve physiological cravings, and normalize body functions. The F.D.A. has approved three drugs for opioid treatment — buprenorphine (often known by the brand name Suboxone), methadone and naltrexone (known by the brand name Vivitrol) — and says they are safe and effective combined with counseling and other support. But the agency said it would soon publish two guidances, recommendations for drugmakers, on the issue.

We provide real treatment that produce real results.

CALL US! (706)495-5896 3642 Wheeler Road Augusta, GA 30909

It’s like killing yourself Don’t face opioid addiction alone. GET HELP TODAY.

3642 Wheeler Road • Augusta, GA 30909 | PH: (706)495-5896

The harsh reality is that opioids are killing thousands of people in this country, many of them young people

State legislators focused on opioid addiction treatment and prevention in schools and prisons Thursday while reviewing bills that would both use medications to thwart overdoses and assist in recovery. A bill making its way through the Legislature would require all schools with grades 9 to 12 to have policies for training nurses on how to administer naloxone. The schools would also have to keep a supply of the medication ready. “The harsh reality is that opioids are killing thousands of people in this country, many of them young people,” Assemblyman Vincent Mazzeo, D-Atlantic, bill sponsor, said in a statement. “Narcan has been proven to save lives. Having it readily available in schools can help ensure that our schools are ready to respond in every emergency situation.” Several South Jersey schools, including Millville, Mainland Regional High School, the Egg Harbor Township School District and the Ocean City School District, already have such policies in place. As of 2017, New Jersey ranked eighth in the nation for drug overdose deaths among people ages 12 to 25, according to the national nonprofit Trust for America’s Health. There have been an estimated 654 overdose deaths in New Jersey since Jan. 1, according to the Department of the Attorney General.

The bill would require that nurses be taught how to use the anti-opioid drug and have a prescription standing order for naloxone to keep it in supply. There were more than 14,300 uses of naloxone in the state last year, state data shows. If passed, the law would also provide immunity from liability for school nurses and other employees when an opioid reversal is performed. Nearby, members of the Assembly Health and Human Services Committee reviewed a bill sponsored by Assemblyman Herb Conaway, D-Burlington, that would require state correctional facilities to offer inmates naltrexone and naloxone just before their release. Naltrexone, known by its brand name Vivitrol, is a type of nonopioid medication- assisted treatment (MAT) for a substance-use disorder. Studies have shown medication-assisted treatments like naltrexone, methadone and buprenorphine have successfully been used to reduce relapse rates and help people maintain recovery from opioid addiction. Vivitrol completely blocks the euphoric and sedative effects of opioids. Recipients often need a monthly shot of the medication administered by a medical professional.

At John Brooks Recovery Centers in Atlantic City and Pleasantville, Vivitrol is just one medication-assisted treatment offered to inpatient and outpatient patients, but it is coupled with counseling and other treatment education. Alan Oberman, CEO of John Brooks Recovery Center, said that while the bill looks well intentioned, giving one shot of Vivitrol, which costs about $1,000, to an outgoing inmate without follow-up or counseling only buys that person about three or four weeks of sobriety before they may use again. “It’s more than just giving an injection, which at least requires a nurse to do it, and many outpatient programs in the community don’t have medical staff there to do it regularly,” he said. While methadone and buprenorphine are MATs that have been on the market for some time, Vivitrol is relatively new. John Brooks and the Atlantic County jail teamed up last summer to create the state’s first mobile methadone program for inmates. Oberman said they now offer inmates Vivitrol, but they haven’t yet had any takers.

(706)495-5896

OPIOID ADDICTION: “LET’S TALK ABOUT IT.” Learn how faith communities can extend COMPASSION & SUPPORT

to people in recovery and to their families

Addiction There is a way out

3642 Wheeler Road Augusta, GA 30909 706-495-5896

Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32

Powered by